Market capitalization | GBP34.78m |
Enterprise Value | GBP40.25m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 21.64 |
P/S ratio (TTM) P/S ratio | 18.70 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -22.16% |
Revenue (TTM) Revenue | GBP1.86m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Renalytix AI plc:
1 Analyst has issued a forecast Renalytix AI plc:
Sep '24 |
+/-
%
|
||
Revenue | 1.86 1.86 |
22%
22%
|
|
Gross Profit | 0.24 0.24 |
31%
31%
|
|
EBITDA | -19 -19 |
41%
41%
|
EBIT (Operating Income) EBIT | -19 -19 |
41%
41%
|
Net Profit | -22 -22 |
38%
38%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Renalytix AI Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in Penarth, the United Kingdom.
Head office | United Kingdom |
CEO | James McCullough |
Founded | 2018 |
Website | renalytix.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.